

To evaluate the effect of surfactant administration in the treatment of term and late preterm neonates with meconium aspiration syndrome (MAS) in relation to outcome (Death/Discharge)

¹Dr. Kirti Bardia, Department of Paeditrics, P.B.M. Hospital, S. P. Medical College, Bikaner.

²Dr. Mukesh Kumar Beniwal, Department of Paeditrics, P.B.M. Hospital, S. P. Medical College, Bikaner.

Corresponding Author: Dr. Kirti Bardia, Department of Paeditrics, P.B.M. Hospital, S. P. Medical College, Bikaner.

How to citation this article: Dr. Kirti Bardia, Dr. Mukesh Kumar Beniwal, “To evaluate the effect of surfactant administration in the treatment of term and late preterm neonates with meconium aspiration syndrome (MAS) in relation to outcome (Death/Discharge)”, IJMACR– August – 2026, Volume – 9, Issue –4, P. No. 198 – 205.

Open Access Article: © 2026 Dr. Kirti Bardia, et al. This is an open access journal and article distributed under the terms of the creative common’s attribution license (<http://creativecommons.org/licenses/by/4.0>). Which allows others to remix, tweak, and build upon the work non- commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Type of Publication: Original Research Article

Conflicts of Interest: Nil

Abstract

Background: The transition from intrauterine to extra uterine life is a critical period for neonates accompanied by significant physiological adjustments. However, complications arising during this transition can lead to significant morbidity and mortality (5% to 12%). To evaluate the effect of surfactant administration in the treatment of term and late preterm neonates with me conium aspiration syndrome (MAS) in relation to outcome (Death/Discharge)

Methods: This study evaluated and compared the clinical outcomes of surfactant administration in term and late preterm neonates with Me conium Aspiration Syndrome (MAS) at P.B.M. Hospital, Bikaner.

Results- Infants who got surfactant early needed oxygen for about 43 hours, compared to about 51 hours for the late group. Ventilation time was also slightly shorter for early treatment (about 8.5 hours vs. 10.4 hours). Hospital stays were almost the same—7.1 days for early and 7.5

days for late. The p-values for all outcomes are above 0.05, suggesting these differences are not statistically significant. In other words, the timing of surfactant made less of a difference in full-term infants than in late preterm newborns. The small differences seen here might not be meaningful in practice.

So, while early surfactant is still a good idea, the biggest benefit is seen in preterm babies rather than those born at full term.

Conclusion: The results highlight that late preterm neonates with MAS experience significantly poorer clinical outcomes compared to term counterparts, including higher mortality, more severe respiratory distress, and prolonged need for respiratory support and hospitalization. Late preterm infants showed greater systemic involvement — evidenced by elevated inflammatory markers, more severe radiographic findings, and lower APGAR scores — reflecting their increased physiological vulnerability. Importantly, early

administration of surfactant was associated with improved clinical outcomes across both groups, notably reducing the duration of mechanical ventilation, oxygen therapy, and hospital stay. These benefits were more pronounced in the late preterm group, suggesting that timely intervention is particularly crucial in this population. While the difference in mortality rates between early and late surfactant administration was not statistically significant, trends indicated a potential survival benefit with early intervention, especially among late preterm neonates. The study emphasizes that early surfactant therapy, guided by clinical severity, can significantly enhance morbidity outcomes even if mortality impacts are variable.

Keywords: Neonates, Surfactant, MAS.

Introduction

The transition from intrauterine to extra uterine life is a critical period for neonates accompanied by significant physiological adjustments. However, complications arising during this transition can lead to significant morbidity and mortality (5% to 12%)¹. Among these, Meconium Aspiration Syndrome (MAS) presents a formidable challenge in term and late preterm neonates, particularly in developing nations where perinatal care infrastructure may be limited. Meconium Aspiration Syndrome (MAS) is a serious respiratory condition that occurs when a newborn inhales a mixture of meconium (the thick, greenish-black substance that forms in the intestines during fetal development) and amniotic fluid into the lungs during or shortly after delivery. Normally meconium is expelled after birth but fetal distress, often caused by hypoxia or intrauterine stress, leads to the passage of meconium into the amniotic fluid, inhalation of which causes severe respiratory issues, lung damage and other complications that need immediate medical care. Meconium is composed

of water (72% to 80%), exfoliated skin cells, lanugos, vernixcaseosa, and gastrointestinal secretions². Three randomized controlled trials confirm some benefits of the administration of several boluses of a natural surfactant in the treatment of MAS. Although overall mortality was no difference between the treatment group and the placebo group in each of these trials, the administration of several doses of a natural preparation was found to improve oxygenation in all three, to reduce the need for ECMO in two, and to reduce the risk of pneumothorax in one.³ Surfactant therapy is one of the newer promising modes of therapeutic interventions in babies with severe MAS⁴⁻⁷. Current evidence would support the use of bolus surfactant therapy on a case by case basis in nurseries with a relatively high mortality associated with MAS, or the lack of availability of other forms of respiratory support such as HFV or NO⁸.

Material and method

Study Setting: The study was conducted in the Department of Paediatrics, PBM Hospital, S. P. Medical College, Bikaner.

Study Design: Prospective observational study

Sample Size: The sample size was calculated based on a previous study that reported prevalence of Meconium Aspiration Syndrome in meconium stained amniotic fluid was taken as 7.7 %, 95 % level of confidence and Error rates at 0.05 levels. Total 110 cases were required to conduct the study.

$$N = \frac{Z^2 P (1-P)}{d^2}$$

$$N = \frac{(1.96)^2 (7.7) (92.3) (5)^2}{100}$$

- N = sample size

- Z^2 = Standard normal deviate (taken as 1.96 for 95 % confidence level)
- P = Expected prevalence of me conium aspiration syndrome in me conium-stained amniotic fluid (taken as 7.7)³⁹
- D = Absolute allowable error (taken as 5%)

Based on the formula, we took sample size as 110 cases.

Sampling Technique:

All neonates with me conium aspiration syndrome in me conium-stained amniotic fluid considering inclusion and exclusion criteria were included in the study till the desired sample size was required.

Results and observations

Table1: Demographic and Baseline Characteristics of the patients in each group.

Parameter	Term group (n=49)	Late Pre-term Group (n=61)	P-value
Male*	35 (71.4%)	44 (72.1%)	0.551
Female*	14 (28.6%)	17 (27.9%)	
Gestational Age**	39.04 ± 1.54	35.00 ± 0.8	
Birth wt.**	2692.86 ± 414.65	2114.29 ± 83.82	
Age at Surfactant Administration(hours)**	2.67 ± 1.29	2.91 ± 1.45	0.376

The demographic and baseline characteristics showed no significant difference between the Term and Late Pre-term groups in terms of gender distribution (male: 71.4% vs. 72.1%, p=.551; female: 28.6% vs. 27.9%). The mean gestational age of term group and late pre-term group were found to be 39.04 ± 1.54 and 35.00 ± 0.8 weeks, respectively. Birth weight was found to be 2692.86 ± 414.65 g in Term group while 2114.29±83.82 in Late Pre-term group. The age at surfactant administration did not differ significantly between the groups (2.67±1.29 vs 2.91±1.45 hours, p=0.376).

Table 2: Number of patients with type of surfactant in each group.

Table 2 compares the types of surfactants administered to two groups, namely, term and late pre-term infants. In

Study Population Inclusion Criteria

Gestation age ≥34 weeks, presence of MSAF or me conium staining of skin, umbilicalcordor nails, non-vigorous babies, presence of respiratory distress (Downes score≥6), chest radiograph suggestive of me conium aspiration and age<48hr.

Exclusion Criteria

- This study excluded congenital abnormalities antenatally diagnosed congenital heart disease, hydrops fetalis, pneumothorax, pulmonary hemorrhage.
- It also excluded babies with septicemia and respiratory distress syndrome.

Table 3, which compares the number of patients receiving different types of surfactant in the Term Group (49 patients) and the Late Pre-term Group (61 patients), the distribution shows that Curo surf was administered to 30 out of 49 term patients (61.2%) and 32 out of 61 late pre-term patients (52.5%). On the other hand, Neo surf was given to 19 out of 49 term patients (38.8%) and 29 out of 61 late pre-term patients (47.5%). These figures indicate a slightly higher percentage of Curo surf use in the term group compared to the late pre-term group, with a higher proportion of Neo surf being used in the late pre-term group. This may reflect availability of brand of surfactant at the time of use.

Table 3: Duration of ventilation (hours), oxygenation (hours) and Hospital Stay (days) in late preterm in relation to the time of surfactant administration

Time of Surfactant Administration	Duration of oxygenation (hours)	P- value	Duration of ventilation (hours)	P-value	Hospital Stay (days)	P- value
≤2Hours	65.22±37.57	<0.001	12.39±12.3	<0.001	7.0±1.46	<0.001
>2Hours	107.79±30.46		30.58±16.70		9.1± 1.41	

Table 3 examines only late pre-term newborns, comparing those who received surfactant within 2 hours to those who received it later. This table compares outcomes based on when they received surfactant. Infants who got surfactant within 2 hours spent much less time needing extra oxygen (about 65 hours) compared to those treated later (about 107hours). The need for ventilation was also shorter if surfactant was given early—just over 12 hours versus more than 30 hours for the late group. Hospital stays were slightly shorter for the early group (7 days vs. nearly 9 days).

The p-values for oxygenation, ventilation time and hospital stay are below 0.001, showing that these differences are statistically significant. This means the results are unlikely to be due to chance. Overall, early surfactant clearly helps late preterm infants recover faster, spend less time in intensive care, and get discharged sooner. Delaying surfactant more than doubles the time these babies need oxygen and ventilation. Early intervention is especially important in this group to reduce complications and hospital time.

Table 4: Duration of ventilation (hours), oxygenation (hours), Hospital Stay (days) in term group in relation to the time of surfactant administration

Time of Surfactant Administration	Duration of oxygenation (hours)	P- value	Duration of ventilation (hours)	P- value	Hospital Stay (days)	P- value
≤2Hours	43.06±29.35	0.378	8.53±8.59	0.580	7.12±1.36	0.333
>2Hours	51.06±30.26		10.44±12.63		7.50±1.27	

This table focuses on term newborns and compares the same outcomes. Here, the difference between early (≤2 hours) and late (>2 hours) surfactant administration is smaller than in late preterm babies. Infants who got surfactant early needed oxygen for about 43 hours, compared to about 51 hours for the late group. Ventilation time was also slightly shorter for early treatment (about 8.5 hours vs. 10.4 hours). Hospital stays were almost the same—7.1 days for early and 7.5 days

for late. The p-values for all outcomes are above 0.05, suggesting these differences are not statistically significant. In other words, the timing of surfactant made less of a difference in full-term infants than in late preterm newborns. The small differences seen here might not be meaningful in practice. So, while early surfactant is still a good idea, the biggest benefit is seen in preterm babies rather than those born at full term.

Table 5: Outcome in terms of death and discharge in various group.

Group	Outcome	Age of Surfactant Administration		Total	P-Value
		≤2Hours	>2Hours		

Late Pre Term	Death	6(26%)	14(36.8%)	20(32.7%)	0.386
	Discharge	17(74%)	24 (63.1%)	41(67.2%)	
Term	Death	2(11.7%)	2 (6.25%)	4(8.16%)	0.502
	Discharge	15(88.2%)	30(93.75%)	45(91.8%)	
Overall	Death	8(20%)	16(22.8%)	24(21.8%)	0.727
	Discharge	32(80%)	54(77.1%)	86(78.2%)	

Table 5 compares the outcome (death or discharge) between babies who received surfactant within 2 hours and those who received it later, across all groups. More deaths occurred among new born s given surfactant after 2 hours (16 vs. 8 overall). In the late pre-term group, the difference is even more notable (14 deaths after late surfactant vs. 6 deaths with early). For term babies, the number of deaths is equal (2 in each group), suggesting less impact of timing in this sub group. More new born s survived and were discharged when they received early surfactant (32 vs 54overall; 17 vs 24 in late pre-term; 15 vs 30 in term) but none of the data was statistically significant. Chi – square analysis was used, and p-value

was calculated. Still, the trend strongly suggests that earlier surfactant saves more lives and improves discharge rates, especially in late pre-term infants. This highlights the importance of fast surfactant delivery to improve survival in this population.

Discussion

Me conium Aspiration Syndrome especially in developing countries contributes in significant cause of respiratory diseases in term and late preterm neonates. However, the severity may be controlled due to improved management practices, still there are significant MAS cases.

Table 6: Summary of our findings with that of previous studies.

Parameter	Present Study Findings	Findings in Published Literature	References
Gestational Age (weeks)	Term:39.04±1.54; Late Preterm: 35.00± 0.80	MAS rare before 34 weeks	[9]
Birth Weight (g)	Term:2692.85 ±414.64; Late Preterm:2114.29±83.82	matches INTER GROWTH – 21 st data	[10]
Gender (%male)	Term: 71.4%;LatePreterm:72.1%	Slight male preponderance or near-Equal sex ratio	[11]
Preeclampsia/ Eclampsia (%)	Higher in late preterm (39.3%) vs. term (2%)	Preeclampsia/PIH increases MAS risk; late preterm higher maternal Risk factors	[12]
Maternal Diabetes Mellitus (%)	Higher in late preterm (26.2%) vs Term (8.2%)	Maternal DM more in late preterm births	[13]
No. of Antenatal checkup	Latepreterm:4.77±0.97; Term:7.34±0.97	Reduced number of antenatal Checkup increases MAS risk	[14]

Shock (%)	Latepreterm:39.3%;Term:4%	Shock is more common in late preterm MAS;	[15]
Cyanosis (%)	Latepreterm:77%;Term:24.4%	Cyanosis, hypoxemia, and severe respiratory distress more common in Preterm MAS	[15]
Hypothermia (%)	Latepreterm: 26.2%; Term: 0%	Hypothermia more frequent with severe illness/ preterm status	[15]
Oxygen Saturation (SpO ₂ %)	Late preterm: 82.0 ± 6.38; Term:88.5± 6.02	Lower SpO ₂ in severe/ late preterm MAS; matches literature	[16]
WBC(cells/mcL)	Late preterm: 12515; 81.48;p=0.02(lower in late pre-term)	WBC often lower in preterm due to immature immune system	[16]
Platelet Count (cells/mcL)	Late preterm: 177023. 90; Term: 223985. 54; P < 0.001 (lower in late preterm)	Thrombocytopenia can occur in late Preterm due to immature immune function	[17]
CRP Positive (%)	Late preterm: 82 %; Term: 40.8%	CRP often elevated in severe MAS; Higher in preterm/infection	[18]
APGARat1min	Term:5.39±0.74 Latepreterm:4.89±0.91	APGAR scores were significantly lower in late preterm newborn compared to term new born	[19]
APGARat5min	Term:6.66±1.00 Latepreterm:5.79±1.24		
Patchy Infiltrates (%)	Late preterm: 54.1 %; Term: 22.4 %; Overall: 40%	Patchy infiltrates =classic MAS finding; Late Preterm more common	[20]
Deaths (%)	Total mortality: 21.% Early surfactant mortality:20 % Late surfactant mortality: 22.8%	Higher mortality in late age of surfactant than early surfactant administration	[21]
Ventilation duration (hrs)	Surfactant within 2 hours: 0.75±10.93 Surfactant after 2 hours: 21.37±17.98	Prolonged ventilation needed when Age of administration is more	[21]
Hospital stay(days)	Surfactant within 2 hours:7.13±1.44 Surfactant after 2 hours:8.34±1.57	Shorter length of hospital stay for those Who received early surfactant	[21]
Oxygenation duration (Hours)	Surfactant within 2 hours: 55.80 ± 35.68 Surfactant after 2 hours: 81.69±41.52	Prolonged oxygenation needed when age of administration is more	[21]

Conclusion

This study evaluated and compared the clinical outcomes of surfactant administration in term and late preterm neonates with Meconium Aspiration Syndrome (MAS) at P.B.M. Hospital, Bikaner.

The results highlight that late preterm neonates with MAS experience significantly poorer clinical outcomes compared to term counterparts, including higher mortality, more severe respiratory distress, and

prolonged need for respiratory support and hospitalization.

Late preterm infants showed greater systemic involvement—evidenced by elevated inflammatory markers, more severe radiographic findings, and lower APGAR scores—reflecting their increased physiological vulnerability. Importantly, early administration of surfactant was associated with improved clinical outcomes across both groups, notably reducing the duration of mechanical ventilation, oxygen therapy, and hospital stay. These benefits were more pronounced in the late preterm group, suggesting that timely intervention is particularly crucial in this population. While the difference in mortality rates between early and late surfactant administration was not statistically significant, trends indicated a potential survival benefit with early intervention, especially among late preterm neonates. The study emphasizes that early surfactant therapy, guided by clinical severity, can significantly enhance morbidity outcomes even if mortality impacts are variable.

In conclusion this study re in forces the importance of evidence - based, early respiratory interventions in reducing complications and improving clinical outcomes in neonates affected by MAS.

Future research should focus on multicenter, randomized trials with larger cohorts to validate these findings and explore the efficacy of different surfactant types and delivery methods. Long-term follow-up assessing neuro developmental outcomes in both term and late pre-term MAS patients is crucial. Evaluating non-invasive surfactant techniques may also offer safer alternatives, especially for vulnerable neonates.

Reference

1. Ahlfeld, S.K. (2020). Me conium Aspiration. In Klieg man RM,, St Geme III JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, editors, *Nelson Textbook of Pediatrics* Vol 1; 21st Edition Philadelphia: Elsevier ;1095.
2. Wis well, T. E., & Bent, R. C. (1993). Me conium staining and the me conium aspiration synd rome: unresolved issues. *Pediatric Clinics of North America*, 40(5), 955-981.
3. El Shahed, A. I., Dargaville, P. A., Ohlsson, A., & Soll, R. (2007). Surfactant for me conium aspiration syndrome in full term/near term infants. *Cochrane Data base of Systematic Reviews*, (3).
4. Moya, F. R., Gadzinowski, J., Bancalari, E., Salinas, V., Kopelman, B., Bancalari, A., & Tsai, H. (2005). A multicenter, randomized, masked, comparison trial of lucinactant, colfoscerilpalmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. *Pediatrics*, 115 (4), 1018- 1029.
5. Auten, R. L., Notter, R. H., Kendig, J. W., Davis, J. M., & Shapiro, D. L. (1991). Surfactant treat ment of full-term newborns with respiratory failure. *Pediatrics*, 87(1), 101-107.
6. Halli day, H. L., Speer, C. P., & Robertson, B. (1996). Treatment of severe me conium aspiration syndrome with porcine surfactant. *European journal of pediatrics*, 155(12), 1047-1051.
7. Findlay, R. D., Taeusch, H. W., & Walther, F. J. (1996). Surfactant replacement therapy for me conium aspiration syndrome. *Pediatrics*, 97(1), 48-52.
8. Dargaville, P. A., & Mills, J. F. (2005). Surfactant therapy for me conium aspiration syndrome. *Drugs*, 65(18), 2569-2591.
9. Rahman, S; Uns worth, J; Vause, S (2013)." Me

- conium in Labour". Obstetrics, Gynaecology and Reproductive Medicine. 23 (8): 247-252. doi:10.1016/j.ogrm.2013.05.007
10. Villar J, Ismail LC, Victora CG, et al. (2014). International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. The Lancet Global Health, 2(8), e511-e521. [https://doi.org/10.1016/S2214-109X\(14\)70182-6](https://doi.org/10.1016/S2214-109X(14)70182-6).
11. Shapiro-Mendoza CK, Tomashek KM, Kotelchuk M, et al. (2008). Risk factors for neonatal morbidity and mortality among "healthy," late preterm newborns. Seminars in Perinatology, 32 (4), 219-226. <https://doi.org/10.1053/j.semperi.2008.07.006>.
12. Madhavi, N., Ratnakumari, G., Naidu, A. S., Narayanarao, S., Prasanthi, T., Harini, C., & Sai Sanjana, J. (2022). Surfactant therapy in meconium aspiration syndrome and its outcome in tertiary care hospital. Global Journal for Research Analysis, 11(10), 607-609. <https://doi.org/10.36106/gjra/7401247>.
13. Khashu M, Narayanan M, Bhargava S, Osiovič H. (2009). Perinatal outcomes associated with preterm birth at 33 to 36 weeks' gestation: a population-based cohort study. Pediatrics, 123 (1), 109-113. <https://doi.org/10.1542/peds.2008-1125>.
14. Abdel Razeq NM, Khader YS, Batieha AM. The incidence, risk factors, and mortality of preterm neonates: A prospective study from Jordan (2012-2013). Journal of Neonatal-Perinatal Medicine. 2017;10(1):29-36. DOI: 10.3233/NPM-160142.
15. Hofer N, Jank K, Stranger V, Pansy J, Resch B. Inflammatory indices in meconium aspiration syndrome. Pediatr Pulmonol. 2016 Jun; 51(6):601-6. doi: 10.1002/ppul.23349. Epub 2015 Dec 10. PMID: 26663621.
16. Roudil, P., Vasselon, C., Trombert-Paviot, B., Berger, C., & Patural, H. (2017). Blood parameters of preterm neonates: Postnatal evolution according to gestational age. International Journal of Laboratory Hematology, 39(3), 317-328. <https://doi.org/10.1111/ijlh.12629>.
17. Alva SR, Ashwini KT, Navya BN. Comparative study of platelet indices between term, preterm, and small for gestational age newborns. Scholars J Appl Med Sci. 2016; 4 (11B): 3985-3989. doi: 10.36347/sjams.2016.V04i11.025.
18. Sharma D, Padmavathi IV, Tabatabaie SA, Farahbakhsh N. Late preterm: a new high risk group in neonatology. J Matern Fetal Neonatal Med. 2021; 34 (16):2717-2730. doi:10.1080/14767058.2019.1670796.
19. Yeganegi M, Bahrami R, Azizi S, Marzbanrad Z, Hajizadeh N, Mirjalili SR, et al. Caesarean section and respiratory system disorders in newborns. Eur J Obstet Gynecol Reprod Biol X 2024; 23:100336. <https://doi.org/10.1016/j.eurox.2024.100336>.
20. Chauhan AV, Mahapatra S, Khare P. Clinical profile of meconium aspiration syndrome with special reference to birth weight, gestational age and immediate outcome at tertiary care centre. Int J Contemporary Pediatr. 2024 Nov; 11(11):1563-1568. doi: 10.18203/2349-3291.ijcp20243082.
21. Lama S, Mahato SK, Chaudhary N, Agarwal N, Pathak S, Kurmi OP, Bhatia B, Agarwal KN. Clinicoradiological observations in meconium aspiration syndrome. JNMA J Nepal Med Assoc. 2018; 56 (210): 895. doi:10.31729/jnma.3566.